Effects of olanzapine combined with aripiprazole on body mass and glycolipid metabolism in patients with schizophrenia

Abstract

Objective To investigate the efficacy of olanzapine combined with low-dose aripiprazole on patients with schizophrenia, and the effect of aripiprazole on weight gain, blood sugar and lipid disorders induced by olanzapine. Methods One hundred patients with schizophrenia admitted to the Third People’s Hospital of Zhaoqing from January 2017 to May 2018 were randomly divided into study group and control group with 50 cases in each group. Patients in control group were treated with olanzapine at a dose of 15mg/d, while patients in study group were treated with aripiprazole at a low dose of 10 mg/d on the basis of treatment for control group. The duration of treatment was 24 weeks. Follow-up was conducted at the time of admission and 4, 12 and 24 weeks after treatment. The body mass, body mass index, glycolipid metabolic indexes (fasting blood sugar, triglyceride, high density lipoprotein, low density lipoprotein, total cholesterol), total score of positive and negative syndrome scale (PANSS) and the occurrence of adverse reactions during treatment were compared between the two groups. Results The body mass and body mass index of study group showed a decreasing trend, while that of control group showed an increasing trend, and the differences between the two groups were statistically significant (P 0.05), however, fasting blood glucose, triglyceride, low density lipoprotein and total cholesterol in control group increased 24 weeks after treatment (P 0.05). There were no serious adverse events during treatment in the both groups. Conclusions Low-dose aripiprazole combined with olanzapine is effective and safe in the treatment of schizophrenia. It also has preventive and therapeutic effects on weight gain, blood sugar and lipid metabolism disorder caused by olanzapine. Key words: Olanzapine; Aripiprazole; Body mass; Blood sugar; Blood lipid